Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial

Nobuyuki Hyakuna, Yoshiko Hashii, Hiroyuki Ishida, Katsutsugu Umeda, Yoshiyuki Takahashi, Masayuki Nagasawa, Hiromasa Yabe, Yozo Nakazawa, Katsuyoshi Koh, Hiroaki Goto, Hiroyuki Fujisaki, Kimikazu Matsumoto, Harumi Kakuda, Michihiro Yano, Akio Tawa, Daisuke Tomizawa, Takashi Taga, Souichi Adachi, Koji Kato

Research output: Contribution to journalArticle

Abstract

In the AML-05 clinical trial conducted by the Japanese Pediatric Leukemia/Lymphoma Group from 2006 to 2010, children with high-risk acute myeloid leukemia (HR AML) received allogeneic hematopoietic stem cell transplantation (allo-HSCT) at first complete remission (CR1). The aim of this study was to investigate the impact of allo-HSCT on the outcome of HR AML. Patients with either monosomy 7, 5q−, t(16;21), Ph1, FLT3-ITD, or induction failure after the first course of chemotherapy were eligible for transplant. Of 53 children with HR AML, 51 received allo-HSCT—45 in CR1, five in CR2, and one with non-CR. t(8;21), t(9;11), and t(16;21) abnormalities were identified in eight, five, and four patients, respectively. The stem cell sources varied—bone marrow in 30 patients, peripheral blood in three, and cord blood in 18. The median follow-up was 62 months. The overall survival (OS) rates at 3 years were 73% and 25% for patients who received transplant at CR1 and ≥CR2, respectively. Multivariable analysis showed that patients with chronic graft-versus-host disease (cGVHD) had better OS. This study supports that allo-HSCT is a suitable treatment for HR AML in CR1. The favorable outcome associated with cGVHD indicates that a graft-versus-leukemia effect might be occurring.

Original languageEnglish
Article numbere27875
JournalPediatric Blood and Cancer
Volume66
Issue number10
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Induction Chemotherapy
Hematopoietic Stem Cell Transplantation
Acute Myeloid Leukemia
Clinical Trials
Graft vs Host Disease
Transplants
Leukemia
Fetal Blood
Lymphoma
Stem Cells
Survival Rate
Bone Marrow
Pediatrics
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. / Hyakuna, Nobuyuki; Hashii, Yoshiko; Ishida, Hiroyuki; Umeda, Katsutsugu; Takahashi, Yoshiyuki; Nagasawa, Masayuki; Yabe, Hiromasa; Nakazawa, Yozo; Koh, Katsuyoshi; Goto, Hiroaki; Fujisaki, Hiroyuki; Matsumoto, Kimikazu; Kakuda, Harumi; Yano, Michihiro; Tawa, Akio; Tomizawa, Daisuke; Taga, Takashi; Adachi, Souichi; Kato, Koji.

In: Pediatric Blood and Cancer, Vol. 66, No. 10, e27875, 01.01.2019.

Research output: Contribution to journalArticle

Hyakuna, N, Hashii, Y, Ishida, H, Umeda, K, Takahashi, Y, Nagasawa, M, Yabe, H, Nakazawa, Y, Koh, K, Goto, H, Fujisaki, H, Matsumoto, K, Kakuda, H, Yano, M, Tawa, A, Tomizawa, D, Taga, T, Adachi, S & Kato, K 2019, 'Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial', Pediatric Blood and Cancer, vol. 66, no. 10, e27875. https://doi.org/10.1002/pbc.27875
Hyakuna, Nobuyuki ; Hashii, Yoshiko ; Ishida, Hiroyuki ; Umeda, Katsutsugu ; Takahashi, Yoshiyuki ; Nagasawa, Masayuki ; Yabe, Hiromasa ; Nakazawa, Yozo ; Koh, Katsuyoshi ; Goto, Hiroaki ; Fujisaki, Hiroyuki ; Matsumoto, Kimikazu ; Kakuda, Harumi ; Yano, Michihiro ; Tawa, Akio ; Tomizawa, Daisuke ; Taga, Takashi ; Adachi, Souichi ; Kato, Koji. / Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. In: Pediatric Blood and Cancer. 2019 ; Vol. 66, No. 10.
@article{f1d39eec0f5348f8be5cf1f7b1e9650e,
title = "Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial",
abstract = "In the AML-05 clinical trial conducted by the Japanese Pediatric Leukemia/Lymphoma Group from 2006 to 2010, children with high-risk acute myeloid leukemia (HR AML) received allogeneic hematopoietic stem cell transplantation (allo-HSCT) at first complete remission (CR1). The aim of this study was to investigate the impact of allo-HSCT on the outcome of HR AML. Patients with either monosomy 7, 5q−, t(16;21), Ph1, FLT3-ITD, or induction failure after the first course of chemotherapy were eligible for transplant. Of 53 children with HR AML, 51 received allo-HSCT—45 in CR1, five in CR2, and one with non-CR. t(8;21), t(9;11), and t(16;21) abnormalities were identified in eight, five, and four patients, respectively. The stem cell sources varied—bone marrow in 30 patients, peripheral blood in three, and cord blood in 18. The median follow-up was 62 months. The overall survival (OS) rates at 3 years were 73{\%} and 25{\%} for patients who received transplant at CR1 and ≥CR2, respectively. Multivariable analysis showed that patients with chronic graft-versus-host disease (cGVHD) had better OS. This study supports that allo-HSCT is a suitable treatment for HR AML in CR1. The favorable outcome associated with cGVHD indicates that a graft-versus-leukemia effect might be occurring.",
author = "Nobuyuki Hyakuna and Yoshiko Hashii and Hiroyuki Ishida and Katsutsugu Umeda and Yoshiyuki Takahashi and Masayuki Nagasawa and Hiromasa Yabe and Yozo Nakazawa and Katsuyoshi Koh and Hiroaki Goto and Hiroyuki Fujisaki and Kimikazu Matsumoto and Harumi Kakuda and Michihiro Yano and Akio Tawa and Daisuke Tomizawa and Takashi Taga and Souichi Adachi and Koji Kato",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/pbc.27875",
language = "English",
volume = "66",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial

AU - Hyakuna, Nobuyuki

AU - Hashii, Yoshiko

AU - Ishida, Hiroyuki

AU - Umeda, Katsutsugu

AU - Takahashi, Yoshiyuki

AU - Nagasawa, Masayuki

AU - Yabe, Hiromasa

AU - Nakazawa, Yozo

AU - Koh, Katsuyoshi

AU - Goto, Hiroaki

AU - Fujisaki, Hiroyuki

AU - Matsumoto, Kimikazu

AU - Kakuda, Harumi

AU - Yano, Michihiro

AU - Tawa, Akio

AU - Tomizawa, Daisuke

AU - Taga, Takashi

AU - Adachi, Souichi

AU - Kato, Koji

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In the AML-05 clinical trial conducted by the Japanese Pediatric Leukemia/Lymphoma Group from 2006 to 2010, children with high-risk acute myeloid leukemia (HR AML) received allogeneic hematopoietic stem cell transplantation (allo-HSCT) at first complete remission (CR1). The aim of this study was to investigate the impact of allo-HSCT on the outcome of HR AML. Patients with either monosomy 7, 5q−, t(16;21), Ph1, FLT3-ITD, or induction failure after the first course of chemotherapy were eligible for transplant. Of 53 children with HR AML, 51 received allo-HSCT—45 in CR1, five in CR2, and one with non-CR. t(8;21), t(9;11), and t(16;21) abnormalities were identified in eight, five, and four patients, respectively. The stem cell sources varied—bone marrow in 30 patients, peripheral blood in three, and cord blood in 18. The median follow-up was 62 months. The overall survival (OS) rates at 3 years were 73% and 25% for patients who received transplant at CR1 and ≥CR2, respectively. Multivariable analysis showed that patients with chronic graft-versus-host disease (cGVHD) had better OS. This study supports that allo-HSCT is a suitable treatment for HR AML in CR1. The favorable outcome associated with cGVHD indicates that a graft-versus-leukemia effect might be occurring.

AB - In the AML-05 clinical trial conducted by the Japanese Pediatric Leukemia/Lymphoma Group from 2006 to 2010, children with high-risk acute myeloid leukemia (HR AML) received allogeneic hematopoietic stem cell transplantation (allo-HSCT) at first complete remission (CR1). The aim of this study was to investigate the impact of allo-HSCT on the outcome of HR AML. Patients with either monosomy 7, 5q−, t(16;21), Ph1, FLT3-ITD, or induction failure after the first course of chemotherapy were eligible for transplant. Of 53 children with HR AML, 51 received allo-HSCT—45 in CR1, five in CR2, and one with non-CR. t(8;21), t(9;11), and t(16;21) abnormalities were identified in eight, five, and four patients, respectively. The stem cell sources varied—bone marrow in 30 patients, peripheral blood in three, and cord blood in 18. The median follow-up was 62 months. The overall survival (OS) rates at 3 years were 73% and 25% for patients who received transplant at CR1 and ≥CR2, respectively. Multivariable analysis showed that patients with chronic graft-versus-host disease (cGVHD) had better OS. This study supports that allo-HSCT is a suitable treatment for HR AML in CR1. The favorable outcome associated with cGVHD indicates that a graft-versus-leukemia effect might be occurring.

UR - http://www.scopus.com/inward/record.url?scp=85069679496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069679496&partnerID=8YFLogxK

U2 - 10.1002/pbc.27875

DO - 10.1002/pbc.27875

M3 - Article

C2 - 31309713

AN - SCOPUS:85069679496

VL - 66

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 10

M1 - e27875

ER -